FrancophonIA/ELRC3.0 huggingface dataset:
English: Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.
Slovenian: Prevladujoči presnovek sofosbuvirja v obtoku Študijo so izvedli z dodatnim voksilaprevirjem 100 mg za doseganje izpostavljenosti voksilaprevirju, ki se pričakuje pri bolnikih z okužbo s HCV.
English: 200 mg/245 mg film-coated tablets emtricitabine/tenofovir disoproxil
Slovenian: 200 mg/245 mg filmsko obložene tablete emtricitabinum/tenofovirum disoproxilum
English: (emtricitabine and tenofovir disoproxil) or any other antiviral medicines that contain tenofovir alafenamide, lamivudine or adefovir dipivoxil.
Slovenian: (emtricitabin in dizoproksiltenofovirat) ali druga protivirusna zdravila, ki vsebujejo alafenamidtenofovirat, lamivudin ali dipivoksiladefovirat.
English: contains sodium This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodiumfree'.
Slovenian: vsebuje natrij To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni "brez natrija".
English: film coated tablets are blue, oval, biconvex tablets, of dimensions 20 mm x 10 mm.
Slovenian: filmsko obložene tablete so modre, ovalne, bikonveksne; dimenzije: 20 mm x 10 mm.
English: contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Slovenian: Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
English: treatment without talking to your doctor first.
Slovenian: ne prenehajte jemati, ne da bi se pred tem posvetovali z zdravnikom.
English: and didanosine is not recommended (see section 4.4).
Slovenian: in didanozina ni priporočljiva (glejte poglavje 4.4).
English: film coated tablets (tablets) are blue, oval, biconvex tablets, of dimensions 20 mm x 10 mm.
Slovenian: filmsko obložene tablete (tableta) so modre, ovalne, bikonveksne; dimenzije: 20 mm x 10 mm.
English: contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'.
Slovenian: vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni "brez natrija".
English: is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents (see section 4.2, 4.4 and 5.1).
Slovenian: je indicirano za zdravljenje mladostnikov, okuženih s HIV-1, z odpornostjo ali toksičnostmi na NRTI, zaradi katere uporaba zdravil prve izbire ni mogoča (glejte poglavja 4.2, 4.4 in 5.1).
English: should not be administered concomitantly (see section 4.4).
Slovenian: se ne sme uporabljati sočasno (glejte poglavje 4.4).
English: The Marketing Authorisation Holder (MAH) shall ensure that all physicians who are expected to prescribe/use Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Imetnik dovoljenja za promet z zdravilom bo zagotovil, da bodo vsi zdravniki, pri katerih se pričakuje, da bodo predpisovali/uporabljali zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: KRKA Farmacéutica, S.L.
Slovenian: España KRKA Farmacéutica, S.L.
English: If you accidentally take more than the recommended dose of Emtricitabine/Tenofovir disoproxil Krka d.d., contact your doctor or nearest emergency department for advice.
Slovenian: Če ste pomotoma zaužili odmerek zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d., višji od priporočenega, se posvetujte z zdravnikom ali poiščite najbližjo urgentno ambulanto.
English: If you become pregnant, or plan to become pregnant, ask your doctor about the potential benefits and risks of therapy with Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: - Če zanosite ali načrtujete zanositev, se posvetujte z zdravnikom o možnih koristih in tveganjih zdravljenja z zdravilom Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: 30 film-coated tablets: EU/1/17/1182/002 90 (3 x 30) film-coated tablets: EU/1/17/1182/004
Slovenian: 30 filmsko obloženih tablet: EU/1/17/1182/002 90 (3 x 30) filmsko obloženih tablet: EU/1/17/1182/004
English: should be initiated by a physician experienced in the management of HIV infection.
Slovenian: mora uvesti zdravnik, ki že ima izkušnje z zdravljenjem okužbe z virusom HIV.
English: should be avoided with concomitant or recent use of nephrotoxic medicinal products.
Slovenian: naj ne bi uporabljali sočasno oziroma neposredno po uporabi nefrotoksičnih zdravil.
English: Separate preparations of emtricitabine and tenofovir disoproxil are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of Emtricitabine/Tenofovir disoproxil Krka d.d..
Slovenian: Posamezni pripravki emtricitabina in dizoproksiltenofovirata so na voljo za zdravljenje okužbe z virusom HIV-1, če je treba prekiniti terapijo ali prilagoditi odmerek ene od učinkovin zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d..
English: should be taken with food.
Slovenian: jemati s hrano.
English: If you notice within 12 hours of the time you usually take Emtricitabine/Tenofovir disoproxil Krka d.d., take the tablet preferably with food as soon as possible.
Slovenian: - Če to opazite v roku 12 ur od časa, ko običajno vzamete zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d., morate tableto vzeti čim prej, najbolje s hrano.
English: Other effects in children Children given emtricitabine very commonly experienced changes in skin colour including darkening of the skin in patches Children commonly experienced low red blood cell count (anaemia).
Slovenian: Drugi učinki pri otrocih Otroci, ki so dobivali emtricitabin, so imeli zelo pogosto spremembe obarvanosti kože, vključno s temno obarvanimi kožnimi lisami.
English: Treatment of HIV-1 infection in the paediatric population There are no clinical studies conducted with emtricitabine/tenofovir disproxil in the paediatric population with HIV-1 infection.
Slovenian: Zdravljenje okužbe s HIV-1 pri pediatrični populaciji Kliničnih študij z emtricitabin/dizoproksiltenofoviratom pri pediatrični populaciji, okuženi s HIV-1, niso izvedli.
English: should be avoided in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1).
Slovenian: se je treba izogniti pri predhodno zdravljenih bolnikih, okuženih s HIV-1, ki so nosilci mutacije K65R (glejte poglavje 5.1).
English: You do not need to take another tablet if you were sick more than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka d.d..
Slovenian: Še ene tablete vam ni treba vzeti, če ste bruhali več kot 1 uro po zaužitju zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d..
English: The safety and efficacy of emtricitabine/tenofovir disoproxil in children under the age of 12 years have not been established.
Slovenian: Varnost in učinkovitost emtricitabin/dizoproksiltenofovirata pri otrocih, starih manj kot 12 let, nista bili dokazani.
English: associated changes in BMD on long term bone health and future fracture risk are currently unknown in paediatric patients - That if bone abnormalities are detected or suspected then consultation with an endocrinologist and/or nephrologist should be obtained
Slovenian: na dolgoročno zdravje kosti in prihodnje tveganje zlomov pri pediatričnih bolnikih trenutno niso znani; - da se je treba ob odkritju kostnih nenormalnosti ali sumu nanje posvetovati z endokrinologom in/ali nefrologom.
English: Talk to your doctor if you are intolerant to lactose (see Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: - Z zdravnikom se posvetujte, če imate intoleranco za laktozo (glejte Zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: Know your hepatitis B virus (HBV) infection status before starting Emtricitabine/Tenofovir disoproxil Krka d.d..
Slovenian: - Ugotovite stanje okužbe z virusom hepatitisa B (HBV) pred začetkom jemanja zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d..
English: In addition, the clinical response to treatment should be closely monitored in patients receiving Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Poleg tega je treba skrbno spremljati klinični odziv na zdravljenje pri bolnikih, ki prejemajo zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: In addition, a K70E substitution in HIV-1 reverse transcriptase has been selected by tenofovir and results in low-level reduced susceptibility to abacavir, emtricitabine, lamivudine and tenofovir.
Slovenian: Poleg tega je izbrana substitucija K70E reverzne transkriptaze HIV-1, ki se razvije s tenofovirjem, povzročila zmanjšano občutljivost za abakavir, emtricitabin, lamivudin in tenofovir.
English: (emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Slovenian: (emtricitabin 200 mg, dizoproksiltenofovirat 245 mg)
English: In study GS-US-104-0352, 89 HIV-1 infected paediatric patients with a median age of 7 years (range
Slovenian: V študiji GS-US-104-0352 je bilo 89 pediatričnih bolnikov, okuženih s HIV-1, z mediano starosti 7 let
English: If you vomit less than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka d.d., take another tablet.
Slovenian: Če bruhate manj kot 1 uro po zaužitju zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d., vzemite še eno tableto.
English: contains two active substances, emtricitabine and tenofovir disoproxil.
Slovenian: vsebuje dve učinkovini, emtricitabin in dizoproksiltenofovirat.
English: without talking to your doctor: see section 3, Do not stop taking Emtricitabine/Tenofovir disoproxil Krka d.d..
Slovenian: ne prenehate jemati, ne da bi se posvetovali z zdravnikom: glejte poglavje 3, Ne prenehajte jemati zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d..
English: and didanosine is not recommended (see section 4.4 and Table 2).
Slovenian: in didanozina ni priporočljiva (glejte poglavje 4.4 in preglednico 2).
English: In study GS-US-104-0352, 97 treatment-experienced patients 2 to < 12 years of age with stable, virologic suppression on stavudine- or zidovudine-containing regimens were randomised to either replace stavudine or zidovudine with tenofovir disoproxil (n = 48) or continue on their original regimen (n = 49) for 48 weeks.
Slovenian: V študiji GS-US-104-0352 so 97 predhodno že zdravljenih bolnikov, starih 2 do < 12 let s stabilno, virološko supresijo z režimom, ki je vseboval stavudin ali zidovudin, randomizirali v skupino, v kateri so stavudin ali zidovudin nadomestili z dizoproksiltenofoviratom (n = 48) ali nadaljevali s prvotnim režimom (n = 49) 48 tednov.
English: Psychiatric disorders: Common:
Slovenian: Psihiatrične motnje: Pogosto:
English: In an open-label randomised clinical study (GS-01-934), antiretroviral-naïve HIV-1 infected adult patients received either a once daily regimen of emtricitabine, tenofovir disoproxil and efavirenz (n = 255) or a fixed combination of lamivudine and zidovudineadministered twice daily and efavirenz once daily (n = 254).
Slovenian: Zdravljenje okužbe z virusom HIV-1: V odprti, randomizirani klinični študiji (GS-01-934) so odrasli bolniki z okužbo HIV-1, ki še niso bili zdravljeni s protiretrovirusnimi zdravili, prejemali režim zdravljenja z emtricitabinom, dizoproksiltenofoviratom in efavirenzom (n=255) enkrat na dan ali fiksno kombinacijo lamivudina in zidovudina dvakrat na dan in efavirenz enkrat na dan (n=254).
English: If serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving Emtricitabine/Tenofovir disoproxil Krka d.d., renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Slovenian: Če je potrjena vrednost serumskega fosfata < 3,0 mg/dl (0,96 mmol/l) pri katerem koli pediatričnem bolniku, ki dobiva zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d., je treba ponovno ovrednotiti ledvično funkcijo v roku enega tedna, vključno z merjenjem koncentracije glukoze in kalija v krvi ter glukoze v urinu (glejte poglavje 4.8, proksimalna tubulopatija).
English: Among 28 patients receiving 96 weeks of treatment with tenofovir disoproxil, BMD Z scores declined by -0.341 for lumbar spine and -0.458 for total body.
Slovenian: ki so se 96 tednov zdravili z dizoproksiltenofoviratom, se je Z-vrednost MGK zmanjšala za -0,341 za ledveno hrbtenico in -0,458 za celo telo.
English: therapy - Recommended schedule for monitoring renal function considering the presence or absence of additional risk factors for renal impairment - That if serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving tenofovir disoproxil, renal function should be re-evaluated within one week.
Slovenian: ; - priporočen urnik spremljanja delovanja ledvic, pri čemer se upošteva prisotnost ali odsotnost dodatnih dejavnikov tveganja za okvare ledvic; - da je treba po enem tednu delovanje ledvic ponovno oceniti, če so potrjene vrednosti serumskega fosfata < 3,0 mg/dl (0,96 mmol/l) pri vsakem pediatričnem bolniku, ki dobiva dizoproksiltenofovirat.
English: If you notice 12 hours or more after the time you usually take Emtricitabine/Tenofovir disoproxil Krka d.d., forget about the missed dose.
Slovenian: - Če to opazite po 12 urah ali več od časa, ko običajno vzamete zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d., pozabljenega odmerka ne vzemite.
English: Tablet core: pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate, stearic acid.
Slovenian: - Druge sestavine zdravila so: Jedro tablete: predgelirani škrob, premreženi natrijev karmelozat, laktoza monohidrat, mikrokristalna celuloza, natrijev stearilfumarat in stearinska kislina.
English: If you have kidney problems, your doctor may advise you to stop taking Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Če imate ledvične težave, vam zdravnik lahko svetuje, da zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: HIV-1infected patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Slovenian: Bolniki s HIV-1, s preeksistentno okrnjeno funkcijo jeter, vključno s kroničnim aktivnim hepatitisom, imajo v času kombinirane protiretrovirusne terapije (combination antiretroviral therapy, CART) več motenj v delovanju jeter.
English: The combination should be used with caution with frequent renal monitoring (see section 4.4).
Slovenian: Kombinacijo je treba uporabljati previdno in pogosto spremljati delovanje ledvic (glejte poglavje 4.4).
English: België/Belgique/Belgien KRKA Belgium, SA.
Slovenian: België/Belgique/Belgien
English: If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 50 mL/min in any patient receiving Emtricitabine/Tenofovir disoproxil Krka d.d., renal function should be reevaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Slovenian: Če je vrednost serumskega fosfata < 1,5 mg/dl (0,48 mmol/l) ali se očistek kreatinina zmanjša na < 50 ml/min, je pri vsakem bolniku, ki prejema zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d., treba ponovno ovrednotiti ledvično funkcijo v roku enega tedna, vključno z merjenjem koncentracije glukoze in kalija v krvi ter glukoze v urinu (glejte poglavje 4.8, proksimalna tubulopatija).
English: Data generated from simultaneous dosing with ledipasvir/sofosbuvir.
Slovenian: n/i = ni izračuna Podatki na podlagi sočasnega odmerjanja ledipasvirja/sofosbuvirja.
English: may cause renal damage monitoring of renal function is recommended (see section 4.4).
Slovenian: povzroči ledvično okvaro, se priporoča nadziranje ledvične funkcije (glejte poglavje 4.4).
English: should be avoided with concurrent or recent use of a nephrotoxic medicinal product (see section 4.5).
Slovenian: naj ne bi uporabljali sočasno oziroma neposredno po uporabi nefrotoksičnih zdravil (glejte poglavje 4.5).
English: Individuals over the age of 65 years are more likely to have decreased renal function, therefore caution should be exercised when administering Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Obstaja večja verjetnost, da je ledvična funkcija pri posameznikih, starejših od 65 let, zmanjšana, zato je pri dajanju zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: There are uncertainties associated with the long-term renal and bone effects of tenofovir disoproxilduring the treatment of HIV-1 infection in the paediatric population.
Slovenian: Z dolgoročnimi učinki dizoproksiltenofovirata na kosti in ledvice med zdravljenjem okužbe s HIV-1 v pediatrični populaciji so povezane negotovosti.
English: should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide or other cytidine analogues, such as lamivudine (see section 4.4).
Slovenian: se ne sme sočasno uporabljati z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat, tenofoviralafenamid ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.4).
English: Based on minimal hepatic metabolism and the renal route of elimination for emtricitabine, it is unlikely that a dose adjustment would be required for Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Na osnovi minimalne jetrne presnove in izločanja emtricitabina preko ledvic je malo verjetno, da bi bila pri bolnikih z jetrno okvaro potrebna prilagoditev odmerka zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or other cytidine analogues, such as lamivudine (see section 4.5).
Slovenian: se ne sme dajati skupaj z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat, tenofoviralafenamid ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.5).
English: is not recommended in individuals under the age 18 years with renal impairment (see section 4.2).
Slovenian: Uporabe se ne priporoča pri posameznikih, starih manj kot 18 let, z ledvično okvaro (glejte poglavje 4.4).
English: Renally eliminated medicinal products: Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Zdravila, ki se izločajo preko ledvic: Ker se emtricitabin in tenofovir izločata predvsem preko ledvic, sočasna uporaba zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: Individuals with renal impairment: Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any adults with renal impairment receiving Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Ker lahko dizoproksiltenofovirat povzroči ledvično toksičnost, se priporoča skrbno nadziranje ledvične funkcije pri vseh odraslih z ledvično okvaro, ki prejemajo zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: use.
Slovenian: izpuščaj
English: is coadministered with an NSAID, renal function should be monitored adequately.
Slovenian: z NSAID je potrebno spremljati ledvično funkcijo.
English: Very common side effects (may affect more than 1 in 10 people) diarrhoea, being sick (vomiting), feeling sick (nausea) dizziness, headache rash feeling weak
Slovenian: Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) - driska, bruhanje, občutek siljenja na bruhanje (navzea) - omotičnost, glavobol
English: If you have HBV, there is a serious risk of liver problems when you stop taking Emtricitabine/Tenofovir disoproxil Krka d.d., whether or not you also have HIV.
Slovenian: Če imate hepatitis B, obstaja resno tveganje za jetrne težave, ko prenehate jemati zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d., ne glede na to, ali imate HIV ali ne. Pomembno je, da zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: is and what it is used for What you need to know before you take Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: Date of opening:___________
Slovenian: Rok uporabnosti po prvem odprtju plastenke: 2 meseca Datum odprtja: ____________
English: is not recommended for use in paediatric patients with renal impairment - That use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: pri pediatričnih bolnikih z ledvično okvaro ne priporoča; - da se je treba uporabi zdravila Emtricitabine/Tenofovir disoproxil Krka d.d.
English: to older people.
Slovenian: starejšim ljudem potrebna previdnost.
English: If you feel dizzy while taking Emtricitabine/Tenofovir disoproxil Krka d.d., do not drive and do not use any tools or machines.
Slovenian: pojavlja omotičnost, ne vozite avtomobila in ne upravljajte z orodji ali stroji.
English: is missed within 12 hours of the time it is usually taken, Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: v roku 12 ur od časa, ko se ga običajno vzame, je treba vzeti zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: What you need to know before you take Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
English: is administered with a third nucleoside analogue.
Slovenian: s tretjim analogom nukleozidov.
English: Renal function (creatinine clearance and serum phosphate) should be evaluated prior to treatment, and should be monitored during use as in adults (see above).
Slovenian: za zdravljenje okužbe s HIV-1 ovrednotiti, nato pa jih je treba med uporabo spremljati kot pri odraslih osebah (glejte zgoraj).
English: AUC: ↓ 29% (↓ 36 to ↓ 22) Cmax: ↓ 41% (↓ 51 to ↓ 29)
Slovenian: AUC: ↓ 29 % (↓ 36 do ↓ 22) Cmax: ↓ 41% (↓ 51 do ↓ 29)
English: If you have hepatitis B, it is especially important not to stop your Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: - Če ste okuženi s hepatitisom B, je še zlasti pomembno, da ne prenehate z zdravljenjem z zdravilom Emtricitabin/dizoproksiltenofovirat Krka d.d., ne da bi se prej posvetovali z zdravnikom.
English: is used with nephrotoxic medicinal products, renal function should be closely monitored according to the recommended schedule - That paediatric patients should have their baseline renal function assessed prior to initiating Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: uporablja skupaj z nefrotoksičnimi zdravili, je treba delovanje ledvic skrbno spremljati po priporočenem urniku; - da je pred začetkom zdravljenja z zdravilom Emtricitabine/Tenofovir disoproxil Krka d.d.
English: Summary of Product Characteristics and an appropriate educational brochure, as detailed below:
Slovenian: za zdravljenje mladostnikov, okuženih z virusom HIV-1, dobili izobraževalni komplet za zdravnike, ki vsebuje Povzetek glavnih značilnosti zdravila in ustrezno izobraževalno brošuro, kot je navedeno spodaj:
English: may cause a reduction in BMD and the effects of Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: vpliva na zmanjšanje MKG in da spremembe MKG zaradi učinkov zdravila Emtricitabine/Tenofovir disoproxil Krka d.d.
English: in patients with creatinine clearance decreased to < 50 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L).
Slovenian: Pri bolnikih z zmanjšanjem očistka kreatinina na < 50 ml/min ali z zmanjšanjem serumskega fosfata na < 1,0 mg/dl (0,32 mmol/l) je treba razmisliti o prekinitvi zdravljenja z zdravilom Emtricitabin/dizoproksiltenofovirat Krka d.d..
English: ORAL CONTRACEPTIVES Norgestimate/Ethinyl oestradiol/Tenofovir disoproxil
Slovenian: PERORALNI KONTRACEPTIVI norgestimat/etinilestradiol/d izoproksiltenofovirat norgestimat:
English: In order to optimise the absorption of tenofovir, it is recommended that Emtricitabine/Tenofovir disoproxil Krka d.d.
Slovenian: Za optimalno absorpcijo tenofovirja se priporoča zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.